Search:
 
Home > AIM > Company Profiles > Sareum

Price

Market

Sector

Market Cap
0.15p (0.00p) 0.00% AIM Medicine and Biotech Research £1.23m
Add to company folder | Print
Articles Financial Data Charts Profile
Related Companies
AGY
 10.00p 0.00%
APH
 4.62p 0.00%
AZH
 p
BBI
 p
CEN
 p
CBF
 2.25p 0.00%
COT
 92.00p 0.00%
CRX
 2.75p 0.00%
CYX
 p
LAC
 p
EVC
 25.75p 0.00%
FUL
 3.00p 0.00%
FUM
 12.50p 0.00%
GMX
 1.75p -22.22% Down
GNI
 p
GWP
 29.00p -9.38% Down
HML
 0.45p 0.00%
MLR
 p
MMG
 6.75p 0.00%
MPM
 14.50p -4.92% Down

Commentary

Structure-based drug discovery business

Recent Articles

Sareum looks for deal 02/05/2008
Seymour Pierce 17/12/2007
Revenue grows at Sareum 02/10/2007
The rise of Empire 10/02/2006

Recent Announcements

End of Offer Period
 16/09/2008
Directorate Change and Update
 29/08/2008
Disposal
 26/08/2008
Directorate Change
 11/07/2008
Directorate Change
 01/07/2008
Change of Broker
 26/06/2008
Three Repeat Business Agreeme
 25/06/2008
Corporate update
 19/06/2008
Restructuring
 14/05/2008
Strategic Review
 02/05/2008
More

Articles from the Sector

GW trims loss 19/11/2008
Asterand 18/11/2008
EU trial cheers Plethora 07/11/2008
IS Pharma 05/11/2008
Animalcare nurturing high-margin growth 03/11/2008
Phynova hails pre-clinical cheer 22/10/2008
e-Therapeutics 20/10/2008
Proximagen Neuroscience 16/10/2008
Tepnel expands with US deal 14/10/2008
Sinclair Pharma 03/10/2008
More

Financial History
Financial Year End 30/06/2004 30/06/2005 30/06/2006 30/06/2007
Currency GBP GBP GBP GBP
Turnover 0.02 0.33 1.48 2.47
Operating Profit -0.12 -1.38 -0.75 -0.73
Pretax Profit -0.12 -1.36 -0.75 -0.72
Earnings After Tax -0.12 0.00 -0.62 -0.53
Profit Available For Dividend 0.00 0.00 0.00 0.00
Ordinary Dividends 0.00 -1.24 0.00 0.00
Retained Profit -0.12 0.00 -0.62 -0.53
Shareholders Funds -0.09 1.32 1.20 1.37
Net Current Assets -0.58 0.42 0.45 0.48
Adjusted Earnings Per Share Undiluted -73.78 -0.42 -0.18 -0.12
Adj Earnings Per Share -73.78 -0.42 -0.18 -0.12
Dividend Per Share 0.00 0.00 0.00 0.00

Company Details

Address 2 Iconix Park, Pampisford, Cambridge, CB22 3EG
Telephone 01223 497 700
Fax 01223 497 701

Executives

Chairman Paul Harper (0.30% holding)
Chief Executive Tim Mitchell (9.30% holding)
Finance Director (0.00% holding)
Director John Reader (9.40% holding)

Main Shareholders

Leonard Licht: 10.2%
David Williams: 9.3%
Joseph Craven: 4.6%
Billam AG: 4.3%

Advisers

Nominated Adviser Grant Thornton
Nominated Broker Hybridan
Solicitors Bircham Dyson Bell
Auditors AGN Shipleys
Registrar Capita Registrars

Commentary

Structure-based drug discovery business

Company Data
Code SAR
Sedol GB00B02RFS
Shares In Issue 818.098 m
Indices Aim
Entry on AIM 11/10/2004
Interim Results Mar
Final Results Oct
Year End Jun
Accounts Due Oct
Int div payment n/a
Fin div payment n/a
Int net div per share nil
Fin net div per share nil
Probable CGT relief Yes